Trial Section
Home / Trial Section / Clinical Trial| Indication | Department | Study Title | Study Phase | Investigator | Contact Person | Status |
|---|---|---|---|---|---|---|
| Diabetes Mellitus | Cardiology | A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared with Dapagliflozin in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin (ACHIEVE-2) | Phase III | Tsung-Hsien Lin | 黃惠鈴 | On-going |
| 慢性腎臟病 | Nephrology | FINE-REAL: A non-interventional study providing insights into the use of finerenone in a routine clinical setting | -- | Yi-Wen Chiu | 陳宜霈 | On-going |
| 角膜塑型 | Ophthalmology | Infinite Overnight Orthokeratology Contact Lenses Clinical Study | Class III | Shiuh-Liang Hsu | 李貞德 | On-going |
| Nephrology | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria | Phase III | Yi-Wen Chiu | 陳宜霈 | On-going | |
| Non-Small Cell Lung Cancer | Chest Medicine | A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50% | Phase III | Jen-Yu Hung | 董俞君 | On-going |
| MAC-LD | Chest Medicine | A Phase 2/3, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) | Phase II | Hung Ling Huang | 杜玟蓉 | On-going |
| Gastric Cancer | Gastroenterology | A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | Phase III | I-Chen Wu | 郭靜芳 | On-going |
| Hepatitis | Hepatobiliary and Pancreatic Medicine | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of AHB-137 with Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients | Phase I | Wan-Long Chuang | 莊心婷 | On-going |
| Lung Cancer | Chest Medicine | SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ?50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression | Phase III | Jen-Yu Hung | 周婉明 | On-going |
| Gastric Cancer | Gastroenterology | A randomized, multicenter, double-blind, phase II study to compare the efficacy and safety of the treatment with ONO-4578 in combination with nivolumab, fluoropyrimidine-based and platinum-based chemotherapy (hereinafter referred to as chemotherapy) with those of the treatment with placebo in combination with nivolumab and chemotherapy in chemotherapy-naive participants with human epidermal growth factor receptor 2 (HER2)-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) | Phase II | I-Chen Wu | 郭靜芳 | On-going |
← Please slide to the left for more information